Effects of intravenous infusion of highly purified vitamin B2 on lipopolysaccharide-induced shock and bacterial infection in mice

European Journal of Pharmacology

Volumn 492, Issue 2-3, 2004, Pages 273-280

  Toyosawa, Toshio ^a   Suzuki, Mamoru ^a   Kodama, Kohtarou ^a   Araki, Seiichi ^a  

^a EISAI CO LTD   (Japan)

Author keywords

I.v. infusion; Nitric oxide; Proinflammatory cytokine; Vitamin B2

Indexed keywords

ACTIVATED PROTEIN C; ANACT C; CYTOKINE; LIPOPOLYSACCHARIDE; NITRIC OXIDE; RIBOFLAVIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL INFECTION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG PURIFICATION; ESCHERICHIA COLI; FATALITY; INFUSION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DETERMINATION; SEPTIC SHOCK; STAPHYLOCOCCUS AUREUS;

ANIMALS; ESCHERICHIA COLI INFECTIONS; INFUSIONS, INTRAVENOUS; LIPOPOLYSACCHARIDES; MALE; MICE; MICE, INBRED ICR; RIBOFLAVIN; SHOCK, SEPTIC; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TIME FACTORS;

EID: 2642536667     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2004.04.004     Document Type: Article

References (23)

1. Araki S., Kagaya K., Kitoh K., Kimura M., Fukazawa Y. Enhancement of resistance to Escherichia coli infection in mice by dihydroheptaprenol, a synthetic polyprenol derivative. Infect. Immun. 55:1987;2164-2170
2. 2. J. Vet. Med. Sci. 57:1995;599-602
3. Barriere S.L., Lowry S.F. An overview of mortality risk prediction in sepsis. Crit. Care Med. 23:1995;376-393
4. Bernard G.R., Vincent J.L., Laterre P.F., LaRosa S.P., Dhainaut J.F., Lopez-Rodriguez A., Steingrub J.S., Garber G.E., Helterbrand J.D., Ely E.W., Fisher C.J. Jr. Efficacy and safety of recombinant human activated protein C for severe sepsis. N. Engl. J. Med. 344:2001;699-709
5. Brivet F.G., Kleinknecht D.J., Loirat P., Landais P.J. Acute renal failure in intensive care units - causes, outcome, and prognostic factors of hospital mortality; a prospective, multicenter study. French Study Group on Acute Renal Failure. Crit. Care Med. 24:1996;192-198
6. Bossink A.W., Paemen L., Jansen P.M., Hack C.E., Thijs L.G., Van Damme J. Plasma levels of the chemokines monocyte chemotactic proteins-1 and -2 are elevated in human sepsis. Blood. 86:1995;3841-3847
7. Cohen J. The immunopathogenesis of sepsis. Nature. 420:2002;885-891
8. Dinarello C.A. Proinflammatory and anti-inflammatory cytokines as mediators in the pathogenesis of septic shock. Chest. 112:1997;321S-329S
9. x) and cytokine levels in patients with septic shock. Res. Commun. Mol. Pathol. Pharmacol. 91:1996;347-356
10. Esmon C.T. Protein C anticoagulant pathway and its role in controlling microvascular thrombosis and inflammation. Crit. Care Med. 29:2001;S48-S51
11. Ershler W.B., Keller E.T. Age-related increased interleukin-6 gene expression, late-life diseases, and frailty. Annu. Rev. Physiol. 51:2000;245-270
12. Gresele P., Momi S., Berrettini M., Nenci G.G., Schwarz H.P., Semeraro N., Colucci M. Activated human protein C prevents thrombin-induced thromboembolism in mice. Evidence that activated protein C reduces intravascular fibrin accumulation through the inhibition of additional thrombin generation. J. Clin. Invest. 101:1998;667-676
13. Gross S.S., Wolin M.S. Nitric oxide: pathophysiological mechanisms. Annu. Rev. Physiol. 57:1995;737-769
14. Kimura M., Suzuki M., Araki S. In vitro and in vivo effects of riboflavin sodium phosphate on the phagocytic activity of peritoneal macrophages in mice. Anim. Sci. Technol. 67:1996;368-373
15. Lolis E., Bucala R. Therapeutic approaches to innate immunity: severe sepsis and septic shock. Nat. Rev., Drug Discov. 2:2003;635-645
16. Marty C., Misset B., Tamion F., Fitting C., Carlet J., Cavaillon J.M. Circulating interleukin-8 concentrations in patients with multiple organ failure of septic and nonseptic origin. Crit. Care Med. 22:1994;673-679
17. Okajima K. Regulation of inflammatory responses by natural anticoagulants. Immunol. Rev. 184:2001;258-274
18. 2 on neutrophil functions in cattle. J. Vet. Med. Sci. 57:1995;493-495
19. Parrillo J.E. Pathogenetic mechanisms of septic shock. N. Engl. J. Med. 328:1993;1471-1477
20. Taylor F.B. Jr., Chang A., Esmon C.T., D'Angelo A., Vigano-D'Angelo S., Blick K.E. Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. J. Clin. Invest. 79:1987;918-925
21. 2 presents a promising therapeutic strategy for sepsis and septic shock. Infect. Immun. 72:2004;1820-1823
22. Unna K., Gresln J.G. Studies of the toxicity and pharmacology of riboflavin. J. Pharmacol. 76:1942;75-80
23. Zempleni J., Galloway J.R., McCormick D.B. Pharmacokinetics of orally and intravenously administered riboflavin in healthy humans. Am. J. Clin. Nutr. 63:1996;54-66